NewLimit raises $435M Series C led by Founders Fund at a $3.1B valuation

NewLimit/Hepatocyte epigenetic reprogramming

NewLimit closed a $435M Series C led by Founders Fund with Thrive Capital, Greenoaks and Quiet Capital, plus returning investors. The company plans to advance its first liver reprogramming medicine into human trials within the coming year.

• Led by Founders Fund; other new investors: Thrive Capital, Greenoaks, Quiet Capital; returning investors include Kleiner Perkins and Eli Lilly Ventures.
• Accelerated timeline to human trials enabled by breakthroughs in liver reprogramming with improved targeting and potency.
• Series C funds development across hepatocyte, immune and vascular reprogramming programs for aging-related diseases.